These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10907965)

  • 1. Lack of interaction between citalopram and the CYP3A4 substrate triazolam.
    Nolting A; Abramowitz W
    Pharmacotherapy; 2000 Jul; 20(7):750-5. PubMed ID: 10907965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.
    Robertson P; Hellriegel ET; Arora S; Nelson M
    Clin Pharmacol Ther; 2002 Jan; 71(1):46-56. PubMed ID: 11823757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam.
    Sugimoto K; Araki N; Ohmori M; Harada K; Cui Y; Tsuruoka S; Kawaguchi A; Fujimura A
    Eur J Clin Pharmacol; 2006 Mar; 62(3):209-15. PubMed ID: 16416305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam.
    Barbhaiya RH; Shukla UA; Kroboth PD; Greene DS
    J Clin Psychopharmacol; 1995 Oct; 15(5):320-6. PubMed ID: 8830062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazolam is ineffective in patients taking rifampin.
    Villikka K; Kivistö KT; Backman JT; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1997 Jan; 61(1):8-14. PubMed ID: 9024169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced effect of triazolam with diltiazem.
    Kosuge K; Nishimoto M; Kimura M; Umemura K; Nakashima M; Ohashi K
    Br J Clin Pharmacol; 1997 Apr; 43(4):367-72. PubMed ID: 9146848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.
    Yasui N; Otani K; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T; Kaneko S
    Ther Drug Monit; 1997 Aug; 19(4):371-4. PubMed ID: 9263374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.
    Villikka K; Varis T; Backman JT; Neuvonen PJ; Kivistö KT
    Eur J Clin Pharmacol; 2001 Sep; 57(6-7):457-60. PubMed ID: 11699609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity.
    Kinirons MT; Lang CC; He HB; Ghebreselasie K; Shay S; Robin DW; Wood AJ
    Br J Clin Pharmacol; 1996 Jan; 41(1):69-72. PubMed ID: 8824695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram.
    Gutierrez M; Abramowitz W
    Pharmacotherapy; 2001 Feb; 21(2):163-8. PubMed ID: 11213852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.
    Gutierrez MM; Rosenberg J; Abramowitz W
    Clin Ther; 2003 Apr; 25(4):1200-10. PubMed ID: 12809966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diltiazem enhances the effects of triazolam by inhibiting its metabolism.
    Varhe A; Olkkola KT; Neuvonen PJ
    Clin Pharmacol Ther; 1996 Apr; 59(4):369-75. PubMed ID: 8612379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA; Rooswinkel RW; Sparidans RW; van Herwaarden AE; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.
    Backman JT; Wang JS; Wen X; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Oct; 66(4):401-7. PubMed ID: 10546924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.
    Schrag ML; Wienkers LC
    Drug Metab Dispos; 2001 Jan; 29(1):70-5. PubMed ID: 11124232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of dosing interval on the pharmacokinetic and pharmacodynamic interactions between the oral adsorbent AST-120 and triazolam in humans.
    Kotegawa T; Tsutsumi K; Morita H; Imai H; Morita M; Yoshizato T; Ohyama T; Uchida S; Watanabe H; Namiki N; Ohashi K
    Eur J Clin Pharmacol; 2012 Dec; 68(12):1605-10. PubMed ID: 22644342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences.
    Greenblatt DJ; von Moltke LL; Harmatz JS; Counihan M; Graf JA; Durol AL; Mertzanis P; Duan SX; Wright CE; Shader RI
    Clin Pharmacol Ther; 1998 Sep; 64(3):278-85. PubMed ID: 9757151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic evaluation of the inhibition of alprazolam by citalopram and fluoxetine.
    Hall J; Naranjo CA; Sproule BA; Herrmann N
    J Clin Psychopharmacol; 2003 Aug; 23(4):349-57. PubMed ID: 12920410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism.
    Varhe A; Olkkola KT; Neuvonen PJ
    Br J Clin Pharmacol; 1996 Apr; 41(4):319-23. PubMed ID: 8730978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.